Action NetraMark - AIAI

NetraMark Holdings Inc (AIAI) Action

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

0,82

( - )

Prix Achat

0,81

Prix Vente

0,84

Volume échangé

0,00 Fourchette du Jour 0,00

0,68 Plage de 52 semaines 1,12

Cap du marché

75,972M

Clôture Veille

0,82

Ouverture

Dernière Transaction

0.84

Dernière heure de transaction

15:30:01

Volume financier

VWAP

Volume moyen (3 m)

$ 34 992

Actions en circulation

92 648 699

Rendement du Dividende (LTM)

Ratio Cours sur Bénéfices

-12,21

Bénéfice par action (BPA)

-0,08

Chiffre d'affairess (LTM)

175,85k

Bénéfice net (LTM)

-6,4M

NetraMark Holdings Inc. provides AI-powered insights and software solutions to trial sponsors, clinical research organizations, and biotechnology companies worldwide. It operates NetraAI platform, an advanced machine learning system purpose-built for analyzing complex clinical trial data to identify... NetraMark Holdings Inc. provides AI-powered insights and software solutions to trial sponsors, clinical research organizations, and biotechnology companies worldwide. It operates NetraAI platform, an advanced machine learning system purpose-built for analyzing complex clinical trial data to identify meaningful patient subpopulations. The company was formerly known as Nurosene Health Inc. and changed its name to NetraMark Holdings Inc. in February 2023. NetraMark Holdings Inc. was founded in 2016 and is headquartered in Toronto, Canada. Show more

Secteur

Healthcare

Industrie

Healthcare Providers & Services

Site Web

www.netramark.com

Siège social

Toronto, Canada

Fondé

2026

NetraMark Holdings Inc est coté dans le secteur Healthcare de la Toronto Stock Exchange avec le ticker AIAI. Le dernier cours de clôture d'NetraMark était de $0,82. Au cours de la dernière année, les actions de NetraMark ont été négociées dans une fourchette de prix de $ 0,68 à $ 1,12.

NetraMark compte actuellement 92 648 699 actions en circulation. La capitalisation boursière d'NetraMark est de $75,97 million. NetraMark a un ratio cours/bénéfice (ratio PE) de -12.21.

NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting

TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI...

NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI...

NetraMark Announces Change To Board Of Directors

TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI...

NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI

TORONTO, May 04, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX: AIAI...

NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026

TORONTO, April 30, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX:...

NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs

TORONTO, April 22, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX:...

Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development

TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX:...

Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain

Publication strengthens NetraMark's case for biomarker-guided enrichment, individualized response modeling, and...

NetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset

TORONTO, March 25, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX:...

NetraMark Unveils AI-Discovered Treatment-Responsive Subgroups in A4 Alzheimer’s Trial at AD/PD Conference

TORONTO, March 19, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (TSX:...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-0.01	-1.20481927711	0.83	0.9	0.79	158457	0.8796279	CS
4	-0.18	-18	1	1.09	0.79	71641	0.92253002	CS
12	-0.27	-24.7706422018	1.09	1.12	0.68	45479	0.91709066	CS
26	-0.2	-19.6078431373	1.02	1.12	0.68	41981	0.92995194	CS
52	-0.2	-19.6078431373	1.02	1.12	0.68	41981	0.92995194	CS
156	-0.2	-19.6078431373	1.02	1.12	0.68	41981	0.92995194	CS
260	-0.2	-19.6078431373	1.02	1.12	0.68	41981	0.92995194	CS

AIAI - Frequently Asked Questions (FAQ)

What is the current NetraMark Holdings Inc share price?

The current share price of NetraMark Holdings Inc is $ 0,82

How many NetraMark Holdings Inc shares are in issue?

NetraMark Holdings Inc has 92 648 699 shares in issue

What is the market cap of NetraMark Holdings Inc?

The market capitalisation of NetraMark Holdings Inc is CAD 75,97M

What is the 1 year trading range for NetraMark Holdings Inc share price?

NetraMark Holdings Inc has traded in the range of $ 0,68 to $ 1,12 during the past year

What is the PE ratio of NetraMark Holdings Inc?

The price to earnings ratio of NetraMark Holdings Inc is -12,21

What is the cash to sales ratio of NetraMark Holdings Inc?

The cash to sales ratio of NetraMark Holdings Inc is 490

What is the registered address of NetraMark Holdings Inc?

The registered address for NetraMark Holdings Inc is 1655 Dupont Street, Toronto, Ontario, M6P 3T1

What is the NetraMark Holdings Inc website address?

The website address for NetraMark Holdings Inc is www.netramark.com

Which industry sector does NetraMark Holdings Inc operate in?

NetraMark Holdings Inc operates in the Healthcare Providers & Services sector

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

NetraMark Holdings Inc (AIAI)

NetraMark Holdings Inc (AIAI) Action

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de NetraMark Holdings Inc

AIAI Dernières nouvelles

NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting

NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum

NetraMark Announces Change To Board Of Directors

NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI

NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026

NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs

Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development

Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain

NetraMark Announces Strategic Oncology Research Collaboration with Fondazione per la Medicina Personalizzata to Analyze Landmark ROME Trial Dataset

NetraMark Unveils AI-Discovered Treatment-Responsive Subgroups in A4 Alzheimer’s Trial at AD/PD Conference

NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting

NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum

NetraMark Announces Change To Board Of Directors

NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI

NetraMark To Open The Market At The Toronto Stock Exchange On May 5, 2026

NetraMark Positioned to Advance Psychedelic Clinical Trials Following U.S. Executive Order, Supported by Peer-Reviewed Research and Active Programs

Netramark Comments on U.S. Executive Order to Accelerate Treatments for Serious Mental Illness and Highlights the Need for Regulatory‑Grade Trial Design in Psychedelic Development

Netramark-Authored, Peer-Reviewed Article Suggests Psychedelics Might Not Only Affect Brain Chemistry, They May Also Involve Quantum-Level Processes Inside the Brain

AIAI - Frequently Asked Questions (FAQ)

AIAI Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Inscrivez-vous GRATUITEMENT et obtenez:

Supprimer les publicités